Cointime

enGene

company

About

enGene is a biotechnology company develops treatment for mucosal diseases through inducing therapeutic proteins of harmful proteins.

  • 51 - 100

Highlights

Total Funding Amount
$17.90M
Funding Rounds
2
Investors
2

Details

Last Funding Type
Series A
Last Funding Money Raised
$6.40M
Industries
Biotechnology,Diabetes,Genetics,Health Care
Founded date
Jan 1, 1999
Number Of Employee
51 - 100
Operating Status
Active

enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$17.90M
enGene has raised a total of $17.90M in funding over 2 rounds. Their latest funding was raised on Jan 26, 2015 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 26, 2015 Series B $11.50M 1 — — Detail
Mar 17, 2008 Series A $6.40M 1 Adams, Harkness & Hill Technology Ventures — Detail

Investors

Number of Lead Investors
Number of Investors
1
2
enGene is funded by 2 investors. Adams, Harkness & Hill Technology Ventures and Inbio Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Adams, Harkness & Hill Technology Ventures Yes Series A
Inbio Ventures — Series B
Cointime
İçerikler
Şirket.